Viracta Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 40
- Market Cap
- $8.7M
- Website
- http://www.viracta.com
- Introduction
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.
Viracta Therapeutics Halts Lymphoma Trial, Explores Strategic Options Amid Financial Constraints
• Viracta Therapeutics has stopped its Phase 2 NAVAL-1 trial for Nana-val in relapsed/refractory EBV+ lymphomas to conserve resources.
• The decision to close the trial was not due to safety concerns, but rather to maximize cash runway during a strategic review.
• The company is exploring strategic alternatives, including a potential merger, licensing agreement, or sale, to enhance shareholder value.
• Viracta will continue assessing Nana-val in a Phase 1b/2 trial for recurrent or metastatic EBV+ nasopharyngeal carcinoma.
© Copyright 2025. All Rights Reserved by MedPath